48 results
8-K
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity
8-K
EX-99.2
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
, but not limited to, statements regarding Aldeyra’s future expectations, plans, and prospects, including without limitation statements regarding: the goals
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
25 Apr 24
Regulation FD Disclosure
7:01am
: the goals, opportunity, and potential forreproxalap, ADX - 2191, ADX - 246, ADX - 248, and ADX - 629; anticipated clinical or regulatory milestones
8-K
EX-99.1
4v2j7rc j5
28 Mar 24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
7:01am
8-K
EX-99.1
f664gk8y9vu55hw 6anu
13 Feb 24
Regulation FD Disclosure
4:00pm
8-K
EX-99.1
z53ybnh3cgds8bdh
4 Jan 24
Other Events
7:00am
8-K
EX-99.2
7vrql
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
kguffq z0mbf4qgb
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
sm5j 95tdo
28 Nov 23
Regulation FD Disclosure
7:16am
8-K
EX-99.1
885togogi2 diu8
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
hptlxv6u6 w80unon39n
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
1sx rjw3i
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.2
txwx 15z6q
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
3tow24qzh0pds
15 Jun 23
Regulation FD Disclosure
7:01am